Day One Biopharmaceuticals, INC Form 4 insider transactions

AI Day1 LLC and affiliated entities have disposed of their entire stake in Day One Biopharmaceuticals following a successful tender offer and merger.

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals in an all-cash transaction at $21.50 per share.

Michael Vasconcelle reports the disposal of all equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals for $21.50 per share in an all-cash transaction.

Day One Biopharmaceuticals has been acquired by Servier Pharmaceuticals for $21.50 per share in an all-cash transaction.

Director Natalie C. Holles reports the disposal of all equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Director Saira Ramasastry reports the disposal of all equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Director John A. Josey reports the disposal of all equity holdings following the successful acquisition of Day One Biopharmaceuticals by Servier Pharmaceuticals.

Director J. Scott Garland reports the disposition of equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Director Habib J. Dable reports the disposition of equity holdings following the completion of Day One Biopharmaceuticals' acquisition by Servier Pharmaceuticals.

Director William Grossman reports the cancellation of equity holdings following the acquisition of Day One Biopharmaceuticals by Servier Pharmaceuticals.

Director Garry A. Nicholson reports the cancellation of equity holdings following the acquisition of Day One Biopharmaceuticals by Servier Pharmaceuticals.

Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, reports the disposal of all equity holdings following the company's acquisition by Servier Pharmaceuticals.

Day One Biopharmaceuticals' COO and CFO, Charles N. York II, was granted 188,000 stock options and 126,000 Restricted Stock Units.

Day One Biopharmaceuticals, Inc. granted stock options and restricted stock units to its Head of Research and Development, Michael Vasconcelles.

Day One Biopharmaceuticals CEO Jeremy Bender was granted 592,000 equity awards, including stock options and restricted stock units, effective January 30, 2026.

Day One Biopharmaceuticals' Chief Commercial Officer, Lauren Merendino, was granted 110,000 stock options and 74,000 restricted stock units.

Day One Biopharmaceuticals' General Counsel and Secretary, Adam Dubow, was granted 105,000 stock options and 70,000 Restricted Stock Units, effective January 30, 2026.

Day One Biopharmaceuticals CEO Jeremy Bender reported gifting 614,450 shares of common stock to various grantor retained annuity trusts as part of estate planning.

Day One Biopharmaceuticals' General Counsel and Secretary, Adam Dubow, reported the settlement of Restricted Stock Units and subsequent sale of shares to cover tax liabilities.

Day One Biopharmaceuticals' COO and CFO, Charles N. York II, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax liabilities.

Day One Biopharmaceuticals' Chief Commercial Officer, Lauren Merendino, reported recent stock acquisitions from RSU vesting and an employee stock purchase plan, alongside a sale to cover tax liabilities.

Day One Biopharmaceuticals CEO Jeremy Bender reported the acquisition of common stock through RSU settlements and a subsequent sale of shares to cover tax liabilities.

Day One Biopharmaceuticals' Director, Habib J. Dable, had stock options repriced to $8.99 per share, contingent on continued service.

Day One Biopharmaceuticals' CEO, Jeremy Bender, had his stock options repriced to $8.99, aligning with the closing market price on the effective date.

Day One Biopharmaceuticals' Director John A. Josey had 162,716 stock options repriced to an exercise price of $8.99, contingent on continued service through November 2026.

Day One Biopharmaceuticals' Director Natalie C. Holles had 178,835 stock options repriced to an exercise price of $8.99, contingent on a retention period.

Day One Biopharmaceuticals' director Garry A Nicholson had over 100,000 stock options repriced to a lower exercise price of $8.99, subject to a retention period.

Day One Biopharmaceuticals' director, J. Scott Garland, had his stock options repriced to a lower exercise price of $8.99, effective November 6, 2025.

Day One Biopharmaceuticals' director, Saira Ramasastry, had her stock options repriced to an exercise price of $8.99 per share, effective November 6, 2025.